{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T07:46:00Z","timestamp":1692603960942},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.leukres.2014.12.012","type":"journal-article","created":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T16:49:29Z","timestamp":1419698969000},"page":"290-295","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic significance of ligands belonging to tumour necrosis factor superfamily in acute lymphoblastic leukaemia"],"prefix":"10.1016","volume":"39","author":[{"given":"L.","family":"Bolkun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lemancewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jablonska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Szumowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Bolkun-Skornicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moniuszko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dzieciol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kloczko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.12.012_bib0210","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2014.12.012_bib0215","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.V77.9.2002.2002","article-title":"Effect of tumor necrosis factor-a on the proliferation of leukemic cells from children with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL): studies of primary leukemic cells and BCP-ALL cell lines","volume":"77","author":"Zhou","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2014.12.012_bib0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.leukres.2014.12.012_bib0225","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2014.12.012_bib0230","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V97.1.198","article-title":"Synthesis and release of B-lymphocyte stimulator from myeloid cells","volume":"97","author":"Nardelli","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0235","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","article-title":"Ashkenazi A interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr Biol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0240","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.192.11.1677","article-title":"A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth","volume":"192","author":"Rennert","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2014.12.012_bib0245","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0250","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1096\/fj.08-124669","article-title":"The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and crosslinking","volume":"23","author":"Kimberley","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.leukres.2014.12.012_bib0255","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2002-02-0558","article-title":"Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival","volume":"100","author":"Novak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0260","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2003-02-0540","article-title":"Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway","volume":"103","author":"Kern","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0265","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.2010.01482.x","article-title":"Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia","volume":"85","author":"Molica","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0270","doi-asserted-by":"crossref","first-page":"e50936","DOI":"10.1371\/journal.pone.0050936","article-title":"Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2014.12.012_bib0275","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0280","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0285","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.leukres.2013.05.014","article-title":"Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features","volume":"37","author":"Lemancewicz","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.12.012_bib0290","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00277-013-1924-9","article-title":"BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma","volume":"93","author":"Bolkun","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0295","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1043-4666(03)00094-2","article-title":"Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes","volume":"24","author":"Ehrlich","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.leukres.2014.12.012_bib0300","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.immuni.2004.11.008","article-title":"TRAIL-R as a negative regulator of innate immune cell responses","volume":"21","author":"Diehl","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2014.12.012_bib0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0083-6729(04)67014-2","article-title":"TRAIL and viral infection","volume":"67","author":"Strater","year":"2004","journal-title":"Vitam Horm"},{"key":"10.1016\/j.leukres.2014.12.012_bib0310","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2003-06-2137","article-title":"TRAIL regulates normal erythroid maturation through an ERK-dependent pathway","volume":"103","author":"Secchiero","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0315","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2002-01-0047","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway","volume":"100","author":"Secchiero","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0320","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00277-005-1077-6","article-title":"Relationships between tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and hematopoietic activity in healthy adults","volume":"84","author":"Choi","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0325","first-page":"3716","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis","volume":"95","author":"Zamai","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0330","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4049\/jimmunol.175.2.1232","article-title":"Elimination of senescent neutrophils by TNF-related apoptosis-inducing ligand","volume":"175","author":"Lum","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0335","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood.V98.7.2183","article-title":"Apo2L\/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma","volume":"98","author":"Chen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0340","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2002-06-1770","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome positive leukemia cells","volume":"101","author":"Uno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0345","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2141.2003.04340.x","article-title":"Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand","volume":"121","author":"Jones","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0350","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation-2009.1.523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2014.12.012_bib0355","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.leukres.2014.12.012_bib0360","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"15","author":"Ng","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0365","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","article-title":"An essential role for BAFF in the normal development of B cells through a BCMA independent pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2014.12.012_bib0370","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2014.12.012_bib0375","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/0008-5472.CAN-10-0300","article-title":"A functional receptor for B cell-activating factor is expressed on human acute lymphoblastic leukemias","volume":"70","author":"Parameswaran","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.12.012_bib0380","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MPH.0b013e31829f3271","article-title":"Raised expression of APRIL in Chinese children with acute lymphoblastic leukemia and its clinical implications","volume":"36","author":"Sun","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0385","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1182\/blood-2008-10-183467","article-title":"BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB\/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells","volume":"113","author":"Fu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.012_bib0390","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2008.07185.x","article-title":"Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0395","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.2008.01099.x","article-title":"Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy","volume":"81","author":"Kim","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2014.12.012_bib0400","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1038\/cddis.2013.179","article-title":"Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis","volume":"6","author":"Ehrhardt","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.leukres.2014.12.012_bib0405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.leu.2402338","article-title":"TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors","volume":"16","author":"Plasilova","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.12.012_bib0410","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1074-7613(00)80400-8","article-title":"Death receptor 5, a new member of the TNFR family, and DR4 induce FADD dependent apoptosis and activate the NF-kappaB pathway","volume":"7","author":"Chaudhary","year":"1997","journal-title":"Immunity"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261400407X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261400407X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T12:15:41Z","timestamp":1598616941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261400407X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S014521261400407X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.12.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of ligands belonging to tumour necrosis factor superfamily in acute lymphoblastic leukaemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}